Klortalidon etkileşimleri

tiyazid diüretik sınıfından Klortalidon (Thalitone, Hygroton) için dizinlediğimiz FDA etiketlerinde ve bilgi sayfalarında 350 belgelenmiş etkileşim var: 35 majör, 269 orta, 44 minör ve bir etiketin anlamlı etkileşim olmadığını bildirdiği 2 çift. Aşağıdaki her kayıt, dayandığı cümleyi alıntılar. Bu ilaç sayfası bir başlangıç noktasıdır; sizin durumunuz için verilmiş bir hüküm değildir.

Klortalidon nasıl görünür

32 sürümün tümü
Klortalidon 12.5 mg tablet: beyaz, dikdörtgen, 6 mm, üzerinde I baskısı var.
I
12.5 mg · beyaz · dikdörtgen · 6 mm
Ingenus
Klortalidon 15 mg tablet: beyaz, serbest biçimli, 7 mm, bir yüzünde L, diğer yüzünde 96 baskısı var.
L / 96
15 mg · beyaz · serbest biçimli · 7 mm
Casper
Klortalidon 25 mg tablet: beyaz, serbest biçimli, 9 mm, bir yüzünde L, diğer yüzünde 99 baskısı var.
L / 99
25 mg · beyaz · serbest biçimli · 9 mm
Casper
Klortalidon 50 mg tablet: yeşil, yuvarlak, 8 mm, çentikli, bir yüzünde 1, diğer yüzünde 3 baskısı var.
1 / 3
50 mg · yeşil · yuvarlak · 8 mm · çentikli
Rising Pharma Holdings

Çizimler, FDA etiketlerindeki ürün bilgilerinden oluşturulmuştur: renk, şekil, boyut ve baskı. 22 firmaya ait 32 belgelenmiş sürüm.

Etikete göre etkileşimler

Majör etkileşimler (35)

  • Amiloridpotasyum tutucu diüretikMajör

    Hyperkalemia occurs commonly (about 10%) when amiloride is used without a kaliuretic diuretic. (Amilorid etiketi, Kutulu uyarı)

  • Arsenik trioksitQT aralığını uzatan ilaçMajör

    The risk of torsade de pointes is related to the extent of QTc prolongation, concomitant administration of QTc prolonging drugs, a history of torsade de pointes, pre-existing QTc interval prolongation, congestive heart failure, administration of potassium-wasting diuretics, or other conditions that result in hypokalemia or hypomagnesemia. (Arsenik trioksit etiketi, Uyarılar ve önlemler)

  • Asetazolamidkarbonik anhidraz inhibitörüMajör

    THALITONE is contraindicated in patients with anuria or hypersensitivity to chlorthalidone or other sulfonamide-derived drugs. (Klortalidon etiketi, Kontrendikasyonlar)

  • Brinzolamidkarbonik anhidraz inhibitörüMajör

    THALITONE is contraindicated in patients with anuria or hypersensitivity to chlorthalidone or other sulfonamide-derived drugs. (Klortalidon etiketi, Kontrendikasyonlar)

  • Bumetanidkıvrım (loop) diüretiğiMajör

    WARNING Bumetanide is a potent diuretic which, if given in excessive amounts, can lead to a profound diuresis with water and electrolyte depletion. (Bumetanid etiketi, Kutulu uyarı)

  • DiazoksitMajör

    CONTRAINDICATIONS PROGLYCEM is contraindicated in patients with: Functional hypoglycemia Hypersensitivity to diazoxide, any of the excipients in PROGLYCEM, or other thiazides (Diazoksit etiketi, Kontrendikasyonlar)

  • Diklorfenamidkarbonik anhidraz inhibitörüMajör

    THALITONE is contraindicated in patients with anuria or hypersensitivity to chlorthalidone or other sulfonamide-derived drugs. (Klortalidon etiketi, Kontrendikasyonlar)

  • DofetilidantiaritmikMajör

    In the DIAMOND trials, 1252 patients were treated with dofetilide and diuretics concomitantly, of whom 493 died compared to 508 deaths among the 1248 patients receiving placebo and diuretics. (Dofetilid etiketi, İlaç etkileşimleri)

  • Dorzolamidkarbonik anhidraz inhibitörüMajör

    THALITONE is contraindicated in patients with anuria or hypersensitivity to chlorthalidone or other sulfonamide-derived drugs. (Klortalidon etiketi, Kontrendikasyonlar)

  • Dorzolamid ve timololkarbonik anhidraz inhibitörüMajör

    THALITONE is contraindicated in patients with anuria or hypersensitivity to chlorthalidone or other sulfonamide-derived drugs. (Klortalidon etiketi, Kontrendikasyonlar)

  • Droperidoldopamin antagonistiMajör

    Droperidol should be administered with extreme caution to patients who may be at risk for development of prolonged QT syndrome (e.g., congestive heart failure, bradycardia, use of a diuretic, cardiac hypertrophy, hypokalemia, hypomagnesemia, or administration of other drugs known to increase the QT interval). (Droperidol etiketi, Kutulu uyarı)

  • EnalaprilatACE inhibitörüMajör

    …sometimes associated with oliguria and/or progressive azotemia, and rarely with acute renal failure and/or death, include those with the following conditions or characteristics: heart failure, hyponatremia, high dose diuretic therapy, recent intensive diuresis or increase in diuretic dose, renal dialysis, or severe volume and/or salt depletion of any etiology. (Enalaprilat etiketi, Uyarılar)

  • Eplerenonaldosteron antagonistiMajör

    …• serum creatinine > 2.0 mg/dL in males or >1.8 mg/dL in females, • creatinine clearance < 50 mL/min, or • concomitant administration of potassium supplements or potassium-sparing diuretics (e.g., amiloride, spironolactone, or triamterene) [see Warnings and Precautions (5.1) , Adverse Reactions (6.2) , Drug Interactions (7) , and Clinical Pharmacology (12.3)… (Eplerenon etiketi, Kontrendikasyonlar)

  • Eptifibatidantitrombosit ilaçMajör

    …of active abnormal bleeding within the previous 30 days Severe hypertension (systolic blood pressure >200 mm Hg or diastolic blood pressure >110 mm Hg) not adequately controlled on antihypertensive therapy Major surgery within the preceding 6 weeks History of stroke within 30 days or any history of hemorrhagic stroke Current or planned administration of another… (Eptifibatid etiketi, Kontrendikasyonlar)

  • Etakrinik asitkıvrım (loop) diüretiğiMajör

    CONTRAINDICATIONS All diuretics, including ethacrynic acid, are contraindicated in anuria. (Etakrinik asit etiketi, Kontrendikasyonlar)

  • Because the use of diuretics can accentuate the diminished intravascular volume, diuretics should be avoided except in the late phase of resolution as described below. (Follitropin etiketi, Uyarılar ve önlemler)

  • GentamisinaminoglikozidMajör

    The concurrent use of gentamicin with potent diuretics, such as ethacrynic acid or furosemide, should be avoided, since certain diuretics by themselves may cause ototoxicity. (Gentamisin etiketi, Kutulu uyarı)

  • Gümüş sülfadiazinsülfonamidMajör

    THALITONE is contraindicated in patients with anuria or hypersensitivity to chlorthalidone or other sulfonamide-derived drugs. (Klortalidon etiketi, Kontrendikasyonlar)

  • Avoid diuretics or laxatives in patients with diarrhea. (İrinotekan etiketi, Uyarılar ve önlemler)

  • İtrakonazolazol antifungalMajör

    Diuretics Eplerenone Contraindicated during and 2 weeks after TOLSURA treatment. (İtrakonazol etiketi, İlaç etkileşimleri)

  • KinaprilACE inhibitörüMajör

    …sometimes associated with oliguria and/or progressive azotemia, and rarely with acute renal failure and/or death, include patients with the following conditions or characteristics: heart failure, hyponatremia, high dose diuretic therapy, recent intensive diuresis or increase in diuretic dose, renal dialysis, or severe volume and/or salt depletion of any etiology. (Kinapril etiketi, Uyarılar)

  • KlozapinantipsikotikMajör

    Use CLOZARIL cautiously in patients with cardiovascular or cerebrovascular disease or conditions predisposing to hypotension (e.g., dehydration, use of antihypertensive medications) [see Dosage and Administration ( 2.2 , 2.6 ), Warnings and Precautions ( 5.2 )]. (Klozapin etiketi, Kutulu uyarı)

  • Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution. (Koriogonadotropin alfa etiketi, Uyarılar)

  • Metazolamidkarbonik anhidraz inhibitörüMajör

    THALITONE is contraindicated in patients with anuria or hypersensitivity to chlorthalidone or other sulfonamide-derived drugs. (Klortalidon etiketi, Kontrendikasyonlar)

  • Metolazontiyazid diüretikMajör

    Other Antihypertensive Drugs When metolazone tablets, USP, are used with other antihypertensive drugs, particular care must be taken to avoid excessive reduction of blood pressure, especially during initial therapy. (Metolazon etiketi, Uyarılar)

  • MinoksidilvazodilatörMajör

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (Minoksidil etiketi, Kutulu uyarı)

  • NeomisinaminoglikozidMajör

    The concurrent use of neomycin with potent diuretics such as ethacrynic acid or furosemide should be avoided, since certain diuretics by themselves may cause ototoxicity. (Neomisin etiketi, Kutulu uyarı)

  • Potasyum sitratpotasyum takviyesiMajör

    The following drug interactions may occur with potassium citrate: Potassium-sparing diuretics: concomitant administration should be avoided since the simultaneous administration of these agents can produce severe hyperkalemia (7.1) (Potasyum sitrat etiketi, İlaç etkileşimleri)

  • SiklosporinimmünosüpresanMajör

    Potassium-Sparing Diuretics Cyclosporine should not be used with potassium-sparing diuretics because hyperkalemia can occur. (Siklosporin etiketi, İlaç etkileşimleri)

  • Sodyum bikarbonatantasitMajör

    Sodium bicarbonate injection is contraindicated in patients who are losing chloride by vomiting or from continuous gastrointestinal suction and in patients receiving diuretics known to produce a hypochloremic alkalosis. (Sodyum bikarbonat etiketi, Kontrendikasyonlar)

  • SülfadiazinsülfonamidMajör

    THALITONE is contraindicated in patients with anuria or hypersensitivity to chlorthalidone or other sulfonamide-derived drugs. (Klortalidon etiketi, Kontrendikasyonlar)

  • THALITONE is contraindicated in patients with anuria or hypersensitivity to chlorthalidone or other sulfonamide-derived drugs. (Klortalidon etiketi, Kontrendikasyonlar)

  • SülfasalazinsülfonamidMajör

    THALITONE is contraindicated in patients with anuria or hypersensitivity to chlorthalidone or other sulfonamide-derived drugs. (Klortalidon etiketi, Kontrendikasyonlar)

  • TadalafilPDE5 inhibitörüMajör

    …coadministration of an alpha-blocker and CIALIS for the treatment of BPH has not been adequately studied, and due to the potential vasodilatory effects of combined use resulting in blood pressure lowering, the combination of CIALIS and alpha-blockers is not recommended for the treatment of BPH. [see Dosage and Administration ( 2.7 ), Drug Interactions ( 7.1 ),… (Tadalafil etiketi, Uyarılar ve önlemler)

  • ZonisamidantikonvülsanMajör

    THALITONE is contraindicated in patients with anuria or hypersensitivity to chlorthalidone or other sulfonamide-derived drugs. (Klortalidon etiketi, Kontrendikasyonlar)

Orta düzey etkileşimler (269)

  • AdrenalinsempatomimetikOrta

    …Precautions (5.6) and Adverse Reactions (6) ]. β-blockers, such as propranolol Cyclopropane or halogenated hydrocarbon anesthetics, such as halothane Antihistamines Thyroid hormones Diuretics Cardiac glycosides, such as digitalis glycosides Quinidine Drugs potentiating hypokalemic effects of epinephrine • Potassium depleting diuretics • Corticosteroids • Theophylline… (Adrenalin etiketi, İlaç etkileşimleri)

  • Alfuzosinalfa blokerOrta

    Postural hypotension/syncope: Care should be taken in patients with symptomatic hypotension or who have had a hypotensive response to other medications or are concomitantly treated with antihypertensive medication or nitrates ( 5.1 ) (Alfuzosin etiketi, Uyarılar ve önlemler)

  • AliskirenantihipertansifOrta

    Effect of chlorthalidone on other drugs Chlorthalidone may add to or potentiate the action of other antihypertensive drugs. (Klortalidon etiketi, İlaç etkileşimleri)

  • Allopurinolksantin oksidaz inhibitörüOrta

    Hypersensitivity reactions to allopurinol tablets may be increased in patients with decreased kidney function receiving thiazide diuretics and allopurinol tablets concurrently. (Allopurinol etiketi, Uyarılar ve önlemler)

  • Alogliptin ve metforminDPP-4 inhibitörüOrta

    Examples: Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs and isoniazid Alogliptin Cytochrome (CYP) P450, CYP-Substrates or Inhibitors Clinical Impact: Insulin Secretagogues and Insulin Insulin and insulin secretagogues… (Alogliptin ve metformin etiketi, İlaç etkileşimleri)

  • AmikasinaminoglikozidOrta

    Ethacrynic Acid, Furosemide, Urea, or Mannitol Some diuretics can enhance aminoglycoside toxicity by altering aminoglycoside concentrations in serum and tissue. (Amikasin etiketi, İlaç etkileşimleri)

  • AmiodaronantiaritmikOrta

    Give special attention to electrolyte and acid-base balance in patients experiencing severe or prolonged diarrhea or in patients receiving concomitant diuretics and laxatives. (Amiodaron etiketi, Uyarılar ve önlemler)

  • Amlodipindihidropiridin kalsiyum kanal blokeriOrta

    Effect of chlorthalidone on other drugs Chlorthalidone may add to or potentiate the action of other antihypertensive drugs. (Klortalidon etiketi, İlaç etkileşimleri)

  • Amlodipin ve atorvastatindihidropiridin kalsiyum kanal blokeriOrta

    Effect of chlorthalidone on other drugs Chlorthalidone may add to or potentiate the action of other antihypertensive drugs. (Klortalidon etiketi, İlaç etkileşimleri)

  • Amlodipin ve benazeprildihidropiridin kalsiyum kanal blokeriOrta

    Effect of chlorthalidone on other drugs Chlorthalidone may add to or potentiate the action of other antihypertensive drugs. (Klortalidon etiketi, İlaç etkileşimleri)

  • Amlodipin ve olmesartandihidropiridin kalsiyum kanal blokeriOrta

    Effect of chlorthalidone on other drugs Chlorthalidone may add to or potentiate the action of other antihypertensive drugs. (Klortalidon etiketi, İlaç etkileşimleri)

  • Amlodipin ve valsartandihidropiridin kalsiyum kanal blokeriOrta

    Effect of chlorthalidone on other drugs Chlorthalidone may add to or potentiate the action of other antihypertensive drugs. (Klortalidon etiketi, İlaç etkileşimleri)

  • Arformoterolbeta adrenerjik agonistOrta

    Xanthine derivatives, steroids, diuretics, or non-potassium sparing diuretics may potentiate hypokalemia or ECG changes. (Arformoterol etiketi, İlaç etkileşimleri)

  • AripiprazolantipsikotikOrta

    Antihypertensive Drugs Due to its alpha-adrenergic antagonism, aripiprazole has the potential to enhance the effect of certain antihypertensive agents. (Aripiprazol etiketi, İlaç etkileşimleri)

  • ArmodafinilMSS uyarıcısıOrta

    There was also a slightly greater proportion of patients on NUVIGIL requiring new or increased use of antihypertensive medications (2.9%) compared to patients on placebo (1.8%). (Armodafinil etiketi, Uyarılar ve önlemler)

  • Asebutololbeta blokerOrta

    Effect of chlorthalidone on other drugs Chlorthalidone may add to or potentiate the action of other antihypertensive drugs. (Klortalidon etiketi, İlaç etkileşimleri)

  • AsenapinantipsikotikOrta

    Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medications, patients with known cardiovascular disease (history of myocardial infarction or ischemic heart disease, heart failure, or conduction abnormalities), and patients… (Asenapin etiketi, Uyarılar ve önlemler)

  • AspirinNSAİİOrta

    …this product or any of its ingredients Ask a doctor before use if stomach bleeding warning applies to you you have a history of stomach problems, such as heartburn you are taking a diuretic you have high blood pressure, heart disease, liver cirrhosis, or kidney disease you have asthma Ask a doctor or pharmacist before use if you are taking a prescription drug… (Aspirin etiketi, Uyarılar)

  • Aspirin ve dipiridamolantitrombosit ilaçOrta

    Diuretics The effectiveness of diuretics in patients with underlying renal or cardiovascular disease may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow and salt and fluid retention. (Aspirin ve dipiridamol etiketi, İlaç etkileşimleri)

  • Atenololbeta blokerOrta

    Effect of chlorthalidone on other drugs Chlorthalidone may add to or potentiate the action of other antihypertensive drugs. (Klortalidon etiketi, İlaç etkileşimleri)

  • Effect of chlorthalidone on other drugs Chlorthalidone may add to or potentiate the action of other antihypertensive drugs. (Klortalidon etiketi, İlaç etkileşimleri)

  • Atomoksetinnoradrenalin geri alım inhibitörüOrta

    Antihypertensive Drugs Prevention or Management Increase the frequency of monitoring blood pressure and adjust atomoxetine oral solution dosage as clinically appropriate. (Atomoksetin etiketi, İlaç etkileşimleri)

  • AvanafilPDE5 inhibitörüOrta

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (Avanafil etiketi, Uyarılar ve önlemler)

  • Azilsartananjiyotensin II reseptör blokeri (ARB)Orta

    Effect of chlorthalidone on other drugs Chlorthalidone may add to or potentiate the action of other antihypertensive drugs. (Klortalidon etiketi, İlaç etkileşimleri)

  • BeksagliflozinSGLT2 inhibitörüOrta

    Patients with impaired renal function (eGFR less than 60 mL/min/1.73 m 2 ) [see Use in Specific Populations ( 8.6 )] , elderly patients, patients with low systolic blood pressure, or patients on loop diuretics may be at increased risk for volume depletion or hypotension. (Beksagliflozin etiketi, Uyarılar ve önlemler)

  • Diuretics Clinical Impact : Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Belladonna ve afyon etiketi, İlaç etkileşimleri)

  • BenazeprilACE inhibitörüOrta

    Effect of chlorthalidone on other drugs Chlorthalidone may add to or potentiate the action of other antihypertensive drugs. (Klortalidon etiketi, İlaç etkileşimleri)

  • Effect of chlorthalidone on other drugs Chlorthalidone may add to or potentiate the action of other antihypertensive drugs. (Klortalidon etiketi, İlaç etkileşimleri)

  • BenzfetaminMSS uyarıcısıOrta

    Amphetamines may decrease the hypotensive effect of antihypertensives. (Benzfetamin etiketi, İlaç etkileşimleri)

  • Betaksololbeta blokerOrta

    Effect of chlorthalidone on other drugs Chlorthalidone may add to or potentiate the action of other antihypertensive drugs. (Klortalidon etiketi, İlaç etkileşimleri)

  • Bisoprololbeta blokerOrta

    Effect of chlorthalidone on other drugs Chlorthalidone may add to or potentiate the action of other antihypertensive drugs. (Klortalidon etiketi, İlaç etkileşimleri)

  • Effect of chlorthalidone on other drugs Chlorthalidone may add to or potentiate the action of other antihypertensive drugs. (Klortalidon etiketi, İlaç etkileşimleri)

  • Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib etiketi, Uyarılar ve önlemler)

  • BrekspiprazolantipsikotikOrta

    Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (Brekspiprazol etiketi, Uyarılar ve önlemler)

  • Brimonidinalfa adrenerjik agonistOrta

    Antihypertensives/Cardiac Glycosides Because brimonidine tartrate ophthalmic solution 0.1% and 0.15% may reduce blood pressure, caution in using drugs such as antihypertensives and/or cardiac glycosides with brimonidine tartrate ophthalmic solution 0.1% and 0.15% is advised. (Brimonidin etiketi, İlaç etkileşimleri)

  • Brimonidin ve timololalfa adrenerjik agonistOrta

    Antihypertensives/Cardiac Glycosides Because brimonidine tartrate/timolol maleate ophthalmic solution may reduce blood pressure, caution in using drugs such as antihypertensives and/or cardiac glycosides with brimonidine tartrate/timolol maleate ophthalmic solution is advised. (Brimonidin ve timolol etiketi, İlaç etkileşimleri)

  • Central Nervous System (CNS) depressants Antihistamines have additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, antianxiety agents, etc.). Antihypertensive drugs Sympathomimetic may reduce the effects of antihypertensive drugs. (Bromfeniramin, psödoefedrin ve dekstrometorfan etiketi, İlaç etkileşimleri)

  • Bromokriptindopamin agonistiOrta

    Use caution in patients taking antihypertensive medications. (Bromokriptin etiketi, Uyarılar ve önlemler)

  • Budesonid ve formoterolkortikosteroidOrta

    Diuretics: Use with caution. (Budesonid ve formoterol etiketi, İlaç etkileşimleri)

  • BuprenorfinopioidOrta

    Examples: cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Buprenorfin etiketi, İlaç etkileşimleri)

  • Examples: Cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Buprenorfin ve nalokson etiketi, İlaç etkileşimleri)

  • Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Butalbital, aspirin, kafein ve kodein etiketi, İlaç etkileşimleri)

  • Examples: cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Butalbital, parasetamol, kafein ve kodein etiketi, İlaç etkileşimleri)

  • D vitaminiVitamin ve mineralOrta

    Tiyazid diüretikler kalsiyum atılımını azaltır; D vitamini ve kalsiyum takviyeleriyle birlikte bu durum, özellikle yaşlı yetişkinlerde hiperkalsemiye yol açabilir. (NIH Office of Dietary Supplements, Vitamin D)

  • DapagliflozinSGLT2 inhibitörüOrta

    Patients with impaired renal function (eGFR less than 60 mL/min/1.73 m 2 ), elderly patients, or patients on loop diuretics may be at increased risk for volume depletion or hypotension. (Dapagliflozin etiketi, Uyarılar ve önlemler)

  • Dapagliflozin ve metforminSGLT2 inhibitörüOrta

    Patients with impaired renal function (eGFR less than 60 mL/min/1.73 m 2 ), elderly patients, or patients on loop diuretics may be at increased risk for volume depletion or hypotension. (Dapagliflozin ve metformin etiketi, Uyarılar ve önlemler)

  • Dekslansoprazolproton pompası inhibitörüOrta

    For patients expected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), health care professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically [see Adverse Reactions (6.2) ] . (Dekslansoprazol etiketi, Uyarılar ve önlemler)

  • DeksmetilfenidatMSS uyarıcısıOrta

    • Antihypertensive Drugs: Monitor blood pressure. (Deksmetilfenidat etiketi, İlaç etkileşimleri)

  • Desipramintrisiklik antidepresanOrta

    Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with NORPRAMIN. (Desipramin etiketi, Uyarılar)

  • …Hyponatremia Concomitant administration of DESMODA with other drugs that may increase the risk of water intoxication with hyponatremia, (e.g., tricyclic antidepressants, selective serotonin re-uptake inhibitors, chlorpromazine, opiate analgesics, thiazide diuretics, NSAIDs, lamotrigine, sulfonylureas, particularly chlorpropamide, oxybutynin and carbamazepine). (Desmopressin etiketi, İlaç etkileşimleri)

  • Also, patients taking diuretics or who are otherwise volume depleted can be at greater risk [see Use in Specific Populations (8.5) and Clinical Pharmacology (12.3) ] . (Desvenlafaksin etiketi, Uyarılar ve önlemler)

  • DietilpropionMSS uyarıcısıOrta

    The pressor effects of diethylpropion and those of other drugs may be additive when the drugs are used concomitantly; conversely, diethylpropion may interfere with antihypertensive drugs (i.e., guanethidine, a-methyldopa). (Dietilpropion etiketi, İlaç etkileşimleri)

  • DiflunisalNSAİİOrta

    Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors, patients who are volume depleted, and the elderly. (Diflunisal etiketi, Uyarılar)

  • Digoksindijital glikozidiOrta

    Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (Digoksin etiketi, Uyarılar ve önlemler)

  • DiklofenakNSAİİOrta

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (Diklofenak etiketi, Uyarılar ve önlemler)

  • Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (Diklofenak ve misoprostol etiketi, Uyarılar ve önlemler)

  • Diltiazemkalsiyum kanal blokeriOrta

    Effect of chlorthalidone on other drugs Chlorthalidone may add to or potentiate the action of other antihypertensive drugs. (Klortalidon etiketi, İlaç etkileşimleri)

  • Doksazosinalfa blokerOrta

    Effect of chlorthalidone on other drugs Chlorthalidone may add to or potentiate the action of other antihypertensive drugs. (Klortalidon etiketi, İlaç etkileşimleri)

  • DokserkalsiferolD vitamini analoğuOrta

    Risk may be increased when used concomitantly with high dose calcium preparations, thiazide diuretics, or vitamin D compounds. (Dokserkalsiferol etiketi, Uyarılar ve önlemler)

  • Drospirenon ve etinilestradioloral kontraseptifOrta

    Medications that may increase serum potassium concentration include ACE inhibitors, angiotensin-II receptor antagonists, potassium-sparing diuretics, potassium supplementation, heparin, aldosterone antagonists, and NSAIDS. (Drospirenon ve etinilestradiol etiketi, Uyarılar ve önlemler)

  • DuloksetinSNRIOrta

    The risk of BP decreases may be greater in patients taking concomitant medications that induce orthostatic hypotension (such as antihypertensives) or are potent CYP1A2 inhibitors [see Drug Interactions ( 7.1 )] and in patients taking duloxetine delayed-release capsules at doses above 60 mg daily. (Duloksetin etiketi, Uyarılar ve önlemler)

  • EmpagliflozinSGLT2 inhibitörüOrta

    Patients with impaired renal function (eGFR less than 60 mL/min/1.73 m 2 ), elderly patients, or patients on loop diuretics may be at increased risk for volume depletion or hypotension. (Empagliflozin etiketi, Uyarılar ve önlemler)

  • Empagliflozin ve metforminSGLT2 inhibitörüOrta

    Patients with impaired renal function (eGFR less than 60 mL/min/1.73 m 2 ), elderly patients, or patients on loop diuretics may be at increased risk for volume depletion or hypotension. (Empagliflozin ve metformin etiketi, Uyarılar ve önlemler)

  • EnalaprilACE inhibitörüOrta

    Effect of chlorthalidone on other drugs Chlorthalidone may add to or potentiate the action of other antihypertensive drugs. (Klortalidon etiketi, İlaç etkileşimleri)

  • Enalapril ve hidroklorotiyazidACE inhibitörüOrta

    Effect of chlorthalidone on other drugs Chlorthalidone may add to or potentiate the action of other antihypertensive drugs. (Klortalidon etiketi, İlaç etkileşimleri)

  • Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (Epoetin alfa etiketi, Uyarılar ve önlemler)

  • Epoprostenolprostaglandin analoğuOrta

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Epoprostenol etiketi, İlaç etkileşimleri)

  • Esmololbeta blokerOrta

    Antihypertensive agents clonidine, guanfacine, or moxonidine: Beta blockers also increase the risk of clonidine-, guanfacine-, or moxonidine-withdrawal rebound hypertension. (Esmolol etiketi, İlaç etkileşimleri)

  • Esomeprazolproton pompası inhibitörüOrta

    For patients expected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), health care professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically [see Adverse Reactions (6.2) ] . (Esomeprazol etiketi, Uyarılar ve önlemler)

  • EssitalopramSSRIOrta

    Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk. (Essitalopram etiketi, Uyarılar ve önlemler)

  • EtodolakNSAİİOrta

    Patients at greater risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors, and the elderly. (Etodolak etiketi, Uyarılar)

  • Felodipindihidropiridin kalsiyum kanal blokeriOrta

    Effect of chlorthalidone on other drugs Chlorthalidone may add to or potentiate the action of other antihypertensive drugs. (Klortalidon etiketi, İlaç etkileşimleri)

  • FenelzinMAO inhibitörüOrta

    …hydrochloride desipramine hydrochloride imipramine hydrochloride doxepin carbamazepine cyclobenzaprine HCl amoxapine maprotiline HCl trimipramine maleate protriptyline HCl mirtazapine Phenelzine sulfate should be used with caution in combination with antihypertensive drugs, including thiazide diuretics and β-blockers, since exaggerated hypotensive effects may result. (Fenelzin etiketi, Uyarılar)

  • Fenoksibenzaminalfa blokerOrta

    Effect of chlorthalidone on other drugs Chlorthalidone may add to or potentiate the action of other antihypertensive drugs. (Klortalidon etiketi, İlaç etkileşimleri)

  • FenoprofenNSAİİOrta

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (Fenoprofen etiketi, Uyarılar ve önlemler)

  • FentanilopioidOrta

    …treatment with Class 1 and Class III antiarrhythmics, 4) treatment with monoamine oxidase inhibitors (MAOI's), 5) concomitant treatment with other drug products known to prolong the QT interval and 6) electrolyte imbalance, in particular hypokalemia and hypomagnesemia, or concomitant treatment with drugs (e.g., diuretics) that may cause electrolyte imbalance. (Fentanil etiketi, Uyarılar ve önlemler)

  • Fentermin ve topiramatMSS uyarıcısıOrta

    In addition, when phentermine and topiramate extended-release capsules are used in conjunction with nonpotassium sparing diuretics this may further potentiate potassium-wasting. (Fentermin ve topiramat etiketi, Uyarılar ve önlemler)

  • FludrokortizonkortikosteroidOrta

    Amphotericin B or potassium-depleting diuretics (benzothiadiazines and related drugs, ethacrynic acid and furosemide)—enhanced hypokalemia. (Fludrokortizon etiketi, İlaç etkileşimleri)

  • Flukonazolazol antifungalOrta

    An effect of this magnitude should not necessitate a change in the fluconazole dose regimen in subjects receiving concomitant diuretics. (Flukonazol etiketi, İlaç etkileşimleri)

  • FluoksetinSSRIOrta

    Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (Fluoksetin etiketi, Uyarılar ve önlemler)

  • FlurbiprofenNSAİİOrta

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (Flurbiprofen etiketi, Uyarılar ve önlemler)

  • Flutikazon ve salmeterolkortikosteroidOrta

    Diuretics: Use with caution. (Flutikazon ve salmeterol etiketi, İlaç etkileşimleri)

  • FluvoksaminSSRIOrta

    Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk. (Fluvoksamin etiketi, Uyarılar ve önlemler)

  • Formoterolbeta adrenerjik agonistOrta

    • Xanthine derivatives, steroids, diuretics, or non-potassium sparing diuretics may potentiate hypokalemia or ECG changes. (Formoterol etiketi, İlaç etkileşimleri)

  • FosinoprilACE inhibitörüOrta

    Effect of chlorthalidone on other drugs Chlorthalidone may add to or potentiate the action of other antihypertensive drugs. (Klortalidon etiketi, İlaç etkileşimleri)

  • Effect of chlorthalidone on other drugs Chlorthalidone may add to or potentiate the action of other antihypertensive drugs. (Klortalidon etiketi, İlaç etkileşimleri)

  • FoskarnetantiviralOrta

    When diuretics are indicated, thiazides are recommended over loop diuretics because the latter inhibit renal tubular secretion, and may impair elimination of FOSCAVIR, potentially leading to toxicity. (Foskarnet etiketi, İlaç etkileşimleri)

  • Furosemidkıvrım (loop) diüretiğiOrta

    Effect of chlorthalidone on other drugs Chlorthalidone may add to or potentiate the action of other antihypertensive drugs. (Klortalidon etiketi, İlaç etkileşimleri)

  • GlimepiridsülfonilüreOrta

    …glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol,… (Glimepirid etiketi, İlaç etkileşimleri)

  • GlipizidsülfonilüreOrta

    …may reduce the glucose-lowering effect of GLUCOTROL XL, leading to worsening glycemic control: atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic… (Glipizid etiketi, İlaç etkileşimleri)

  • Guanfasinalfa adrenerjik agonistOrta

    Effect of chlorthalidone on other drugs Chlorthalidone may add to or potentiate the action of other antihypertensive drugs. (Klortalidon etiketi, İlaç etkileşimleri)

  • HaloperidolantipsikotikOrta

    Caution is advised when haloperidol decanoate is used in combination with drugs known to cause electrolyte imbalance (e.g., diuretics or corticosteroids) because hypokalemia, hypomagnesemia, and hypocalcemia are risk factors for QT prolongation. (Haloperidol etiketi, İlaç etkileşimleri)

  • HidralazinvazodilatörOrta

    Effect of chlorthalidone on other drugs Chlorthalidone may add to or potentiate the action of other antihypertensive drugs. (Klortalidon etiketi, İlaç etkileşimleri)

  • Hidroklorotiyazidtiyazid diüretikOrta

    Effect of chlorthalidone on other drugs Chlorthalidone may add to or potentiate the action of other antihypertensive drugs. (Klortalidon etiketi, İlaç etkileşimleri)

  • HidrokodonopioidOrta

    Example: Cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Hidrokodon etiketi, İlaç etkileşimleri)

  • Diuretics : Hydrocodone may reduce the efficacy of diuretics. (Hidrokodon ve homatropin etiketi, İlaç etkileşimleri)

  • Patients taking angiotensin converting enzyme (ACE) inhibitors, thiazide diuretics, or loop diuretics may have impaired response to these therapies when taking NSAIDs (see PRECAUTIONS: Drug Interactions). (Hidrokodon ve ibuprofen etiketi, Uyarılar)

  • Diuretics : Hydrocodone may reduce the efficacy of diuretics. (Hidrokodon ve klorfeniramin etiketi, İlaç etkileşimleri)

  • Diuretics Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Hidrokodon ve parasetamol etiketi, İlaç etkileşimleri)

  • HidromorfonopioidOrta

    Examples: cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Hidromorfon etiketi, İlaç etkileşimleri)

  • İbuprofenNSAİİOrta

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (İbuprofen etiketi, Uyarılar ve önlemler)

  • Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE-inhibitors or ARBs, and the elderly. (İbuprofen ve famotidin etiketi, Uyarılar ve önlemler)

  • İloperidonantipsikotikOrta

    Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive medications), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (İloperidon etiketi, Uyarılar ve önlemler)

  • İmipramintrisiklik antidepresanOrta

    Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with imipramine hydrochloride tablets. (İmipramin etiketi, Uyarılar)

  • İndapamidtiyazid diüretikOrta

    Effect of chlorthalidone on other drugs Chlorthalidone may add to or potentiate the action of other antihypertensive drugs. (Klortalidon etiketi, İlaç etkileşimleri)

  • İndometazinNSAİİOrta

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (İndometazin etiketi, Uyarılar ve önlemler)

  • İnsülin aspartinsülinOrta

    Drugs That May Decrease the Blood Glucose Lowering Effect of Insulin Aspart Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g.,… (İnsülin aspart etiketi, İlaç etkileşimleri)

  • İnsülin degludekinsülinOrta

    Drugs That May Decrease the Blood Glucose Lowering Effect of Insulin Degludec Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g.,… (İnsülin degludek etiketi, İlaç etkileşimleri)

  • İnsülin detemirinsülinOrta

    Drugs That May Decrease the Blood Glucose Lowering Effect of LEVEMIR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol,… (İnsülin detemir etiketi, İlaç etkileşimleri)

  • İnsülin glarjininsülinOrta

    Drugs that May Decrease the Blood Glucose Lowering Effect of Insulin Glargine-yfgn Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents… (İnsülin glarjin etiketi, İlaç etkileşimleri)

  • İnsülin lisproinsülinOrta

    Drugs That May Decrease the Blood Glucose Lowering Effect of LYUMJEV Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol,… (İnsülin lispro etiketi, İlaç etkileşimleri)

  • İpratropium ve salbutamolantikolinerjikOrta

    Diuretics The electrocardiogram (ECG) changes and/or hypokalemia that may result from the administration of non-potassium sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by β-agonists, especially when the recommended dose of the β-agonist is exceeded. (İpratropium ve salbutamol etiketi, İlaç etkileşimleri)

  • İrbesartananjiyotensin II reseptör blokeri (ARB)Orta

    Effect of chlorthalidone on other drugs Chlorthalidone may add to or potentiate the action of other antihypertensive drugs. (Klortalidon etiketi, İlaç etkileşimleri)

  • İrbesartan ve hidroklorotiyazidanjiyotensin II reseptör blokeri (ARB)Orta

    Effect of chlorthalidone on other drugs Chlorthalidone may add to or potentiate the action of other antihypertensive drugs. (Klortalidon etiketi, İlaç etkileşimleri)

  • İsradipindihidropiridin kalsiyum kanal blokeriOrta

    Effect of chlorthalidone on other drugs Chlorthalidone may add to or potentiate the action of other antihypertensive drugs. (Klortalidon etiketi, İlaç etkileşimleri)

  • Effect of chlorthalidone on other drugs Chlorthalidone may add to or potentiate the action of other antihypertensive drugs. (Klortalidon etiketi, İlaç etkileşimleri)

  • KalsitriolD vitamini analoğuOrta

    Thiazides Thiazides are known to induce hypercalcemia by the reduction of calcium excretion in urine. (Kalsitriol etiketi, İlaç etkileşimleri)

  • Drugs That Increase the Risk of Hypercalcemia Increase frequency of monitoring of calcium concentrations in patients taking concomitant Calcium Chloride Injection and other drugs that increase the risk of hypercalcemia (e.g., calcipotriene, estrogen, lithium, parathyroid hormone, teriparatide, thiazide diuretics, Vitamin A, and Vitamin D). (Kalsiyum klorür etiketi, İlaç etkileşimleri)

  • KanagliflozinSGLT2 inhibitörüOrta

    Patients with impaired renal function (eGFR less than 60 mL/min/1.73 m 2 ), elderly patients, or patients on loop diuretics may be at increased risk for volume depletion or hypotension. (Kanagliflozin etiketi, Uyarılar ve önlemler)

  • Kandesartananjiyotensin II reseptör blokeri (ARB)Orta

    Effect of chlorthalidone on other drugs Chlorthalidone may add to or potentiate the action of other antihypertensive drugs. (Klortalidon etiketi, İlaç etkileşimleri)

  • Kandesartan ve hidroklorotiyazidanjiyotensin II reseptör blokeri (ARB)Orta

    Effect of chlorthalidone on other drugs Chlorthalidone may add to or potentiate the action of other antihypertensive drugs. (Klortalidon etiketi, İlaç etkileşimleri)

  • KaptoprilACE inhibitörüOrta

    Effect of chlorthalidone on other drugs Chlorthalidone may add to or potentiate the action of other antihypertensive drugs. (Klortalidon etiketi, İlaç etkileşimleri)

  • KarbamazepinantikonvülsanOrta

    Elderly patients and patients treated with diuretics are at greater risk of developing hyponatremia. (Karbamazepin etiketi, Uyarılar ve önlemler)

  • Symptomatic postural hypotension has occurred when carbidopa, given with levodopa or carbidopa-levodopa combination products, was added to the treatment of a patient receiving antihypertensive drugs. (Karbidopa etiketi, İlaç etkileşimleri)

  • Karbidopa ve levodopadopaminerjik ilaçOrta

    Antihypertensive drugs: May cause symptomatic postural hypotension. (Karbidopa ve levodopa etiketi, İlaç etkileşimleri)

  • Karbidopa, levodopa ve entakapondopaminerjik ilaçOrta

    Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (Karbidopa, levodopa ve entakapon etiketi, İlaç etkileşimleri)

  • KariprazinantipsikotikOrta

    Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive medications), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (Kariprazin etiketi, Uyarılar ve önlemler)

  • Karvedilolbeta blokerOrta

    Effect of chlorthalidone on other drugs Chlorthalidone may add to or potentiate the action of other antihypertensive drugs. (Klortalidon etiketi, İlaç etkileşimleri)

  • KetiapinantipsikotikOrta

    Quetiapine should be used with particular caution in patients with known cardiovascular disease (history of myocardial infarction or ischemic heart disease, heart failure, or conduction abnormalities), cerebrovascular disease, or conditions which would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications). (Ketiapin etiketi, Uyarılar ve önlemler)

  • Ketokonazolazol antifungalOrta

    Diuretics eplerenone The potential increase in plasma concentrations of eplerenone when coadministered with ketoconazole tablets may increase the risk of hyperkalemia and hypotension. (Ketokonazol etiketi, İlaç etkileşimleri)

  • KetoprofenNSAİİOrta

    Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics, and the elderly. (Ketoprofen etiketi, Uyarılar ve önlemler)

  • KetorolakNSAİİOrta

    Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors, and the elderly. (Ketorolak etiketi, Uyarılar ve önlemler)

  • Kinapril ve hidroklorotiyazidACE inhibitörüOrta

    Effect of chlorthalidone on other drugs Chlorthalidone may add to or potentiate the action of other antihypertensive drugs. (Klortalidon etiketi, İlaç etkileşimleri)

  • KinidinantiaritmikOrta

    Drugs that alkalinize the urine ( carbonic-anhydrase inhibitors, sodium bicarbonate, thiazide diuretics ) reduce renal elimination of quinidine. (Kinidin etiketi, İlaç etkileşimleri)

  • KlofarabinantimetabolitOrta

    Consider use of diuretics and/or albumin. (Klofarabin etiketi, Uyarılar ve önlemler)

  • Klonidinalfa adrenerjik agonistOrta

    Effect of chlorthalidone on other drugs Chlorthalidone may add to or potentiate the action of other antihypertensive drugs. (Klortalidon etiketi, İlaç etkileşimleri)

  • Klorotiyazidtiyazid diüretikOrta

    Effect of chlorthalidone on other drugs Chlorthalidone may add to or potentiate the action of other antihypertensive drugs. (Klortalidon etiketi, İlaç etkileşimleri)

  • KlorpromazinantipsikotikOrta

    Thiazide diuretics may accentuate the orthostatic hypotension that may occur with phenothiazines. (Klorpromazin etiketi, Önlemler)

  • KodeinopioidOrta

    Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Kodein etiketi, İlaç etkileşimleri)

  • Kolestiraminsafra asidi bağlayıcıOrta

    Drug Interactions Cholestyramine for Oral Suspension USP may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic), or propranolol (basic), as well as tetracycline, penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis. (Kolestiramin etiketi, İlaç etkileşimleri)

  • Labetalolbeta blokerOrta

    Effect of chlorthalidone on other drugs Chlorthalidone may add to or potentiate the action of other antihypertensive drugs. (Klortalidon etiketi, İlaç etkileşimleri)

  • Lansoprazolproton pompası inhibitörüOrta

    For patients expected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), health care professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically [see Adverse Reactions (6.2) ] . (Lansoprazol etiketi, Uyarılar ve önlemler)

  • Also, patients taking diuretics or who are otherwise volume depleted can be at greater risk. (Levomilnasipran etiketi, Uyarılar ve önlemler)

  • LevorfanolopioidOrta

    Diuretics Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Levorfanol etiketi, İlaç etkileşimleri)

  • Levosalbutamolbeta adrenerjik agonistOrta

    Diuretics The ECG changes or hypokalemia that may result from the administration of non-potassium-sparing diuretics (such as loop and thiazide diuretics) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. (Levosalbutamol etiketi, İlaç etkileşimleri)

  • LinezolidantibiyotikOrta

    Monitor serum sodium levels regularly in the elderly, in patients taking diuretics, and in other patients at risk of hyponatremia and/or SIADH while taking Linezolid injection. (Linezolid etiketi, Uyarılar ve önlemler)

  • LisinoprilACE inhibitörüOrta

    Effect of chlorthalidone on other drugs Chlorthalidone may add to or potentiate the action of other antihypertensive drugs. (Klortalidon etiketi, İlaç etkileşimleri)

  • Effect of chlorthalidone on other drugs Chlorthalidone may add to or potentiate the action of other antihypertensive drugs. (Klortalidon etiketi, İlaç etkileşimleri)

  • Lityumserotonerjik ilaçOrta

    Lithium renal clearance is reduced by chlorthalidone, increasing the risk of lithium toxicity. (Klortalidon etiketi, İlaç etkileşimleri)

  • Lofeksidinalfa adrenerjik agonistOrta

    Effect of chlorthalidone on other drugs Chlorthalidone may add to or potentiate the action of other antihypertensive drugs. (Klortalidon etiketi, İlaç etkileşimleri)

  • Losartananjiyotensin II reseptör blokeri (ARB)Orta

    Effect of chlorthalidone on other drugs Chlorthalidone may add to or potentiate the action of other antihypertensive drugs. (Klortalidon etiketi, İlaç etkileşimleri)

  • Losartan ve hidroklorotiyazidanjiyotensin II reseptör blokeri (ARB)Orta

    Effect of chlorthalidone on other drugs Chlorthalidone may add to or potentiate the action of other antihypertensive drugs. (Klortalidon etiketi, İlaç etkileşimleri)

  • LumateperonantipsikotikOrta

    Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (Lumateperon etiketi, Uyarılar ve önlemler)

  • LurasidonantipsikotikOrta

    Patients at increased risk of these adverse reactions or at increased risk of developing complications from hypotension include those with dehydration, hypovolemia, treatment with antihypertensive medication, history of cardiovascular disease (e.g., heart failure, myocardial infarction, ischemia, or conduction abnormalities), history of cerebrovascular disease,… (Lurasidon etiketi, Uyarılar ve önlemler)

  • Mefenamik asitNSAİİOrta

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (Mefenamik asit etiketi, Uyarılar ve önlemler)

  • MekamilaminantihipertansifOrta

    Effect of chlorthalidone on other drugs Chlorthalidone may add to or potentiate the action of other antihypertensive drugs. (Klortalidon etiketi, İlaç etkileşimleri)

  • MeloksikamNSAİİOrta

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (Meloksikam etiketi, Uyarılar ve önlemler)

  • MetadonopioidOrta

    Closely monitor patients with risk factors for development of prolonged QT interval (e.g., cardiac hypertrophy, concomitant diuretic use, hypokalemia, hypomagnesemia), a history of cardiac conduction abnormalities, and those taking medications affecting cardiac conduction. (Metadon etiketi, Uyarılar ve önlemler)

  • MetildopaantihipertansifOrta

    Effect of chlorthalidone on other drugs Chlorthalidone may add to or potentiate the action of other antihypertensive drugs. (Klortalidon etiketi, İlaç etkileşimleri)

  • MetilfenidatMSS uyarıcısıOrta

    Antihypertensive Drugs: Monitor blood pressure. (Metilfenidat etiketi, İlaç etkileşimleri)

  • Metoprololbeta blokerOrta

    Effect of chlorthalidone on other drugs Chlorthalidone may add to or potentiate the action of other antihypertensive drugs. (Klortalidon etiketi, İlaç etkileşimleri)

  • Effect of chlorthalidone on other drugs Chlorthalidone may add to or potentiate the action of other antihypertensive drugs. (Klortalidon etiketi, İlaç etkileşimleri)

  • MilnasipranSNRIOrta

    Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Geriatric Use ( 8.5 )] . (Milnasipran etiketi, Uyarılar ve önlemler)

  • MirtazapinantidepresanOrta

    Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia [see Use in Specific Populations (8.5) ] . (Mirtazapin etiketi, Uyarılar ve önlemler)

  • ModafinilMSS uyarıcısıOrta

    However, a retrospective analysis of the use of antihypertensive medication in these studies showed that a greater proportion of patients on PROVIGIL required new or increased use of antihypertensive medications (2.4%) compared to patients on placebo (0.7%). (Modafinil etiketi, Uyarılar ve önlemler)

  • MoeksiprilACE inhibitörüOrta

    Effect of chlorthalidone on other drugs Chlorthalidone may add to or potentiate the action of other antihypertensive drugs. (Klortalidon etiketi, İlaç etkileşimleri)

  • MorfinopioidOrta

    Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Morfin etiketi, İlaç etkileşimleri)

  • NabumetonNSAİİOrta

    Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics, and the elderly. (Nabumeton etiketi, Uyarılar)

  • Nadololbeta blokerOrta

    Effect of chlorthalidone on other drugs Chlorthalidone may add to or potentiate the action of other antihypertensive drugs. (Klortalidon etiketi, İlaç etkileşimleri)

  • NalbufinopioidOrta

    Diuretics Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Nalbufin etiketi, İlaç etkileşimleri)

  • NaproksenNSAİİOrta

    ( 5.3 Hepatotoxicity) Hypertension: Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (Naproksen etiketi, Uyarılar ve önlemler)

  • Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE-inhibitors or ARBs, and the elderly. (Naproksen ve esomeprazol etiketi, Uyarılar ve önlemler)

  • NateglinidmeglitinidOrta

    Drugs and Herbals That May Reduce the Blood-Glucose-Lowering Effect of Nateglinide and Increase Susceptibility to Hyperglycemia Drugs: Thiazides, corticosteroids, thyroid products, sympathomimetics, somatropin, somatostatin analogues (e.g., lanreotide, octreotide), and CYP inducers (e.g., rifampin, phenytoin and St John's Wort). (Nateglinid etiketi, İlaç etkileşimleri)

  • Nebivololbeta blokerOrta

    Effect of chlorthalidone on other drugs Chlorthalidone may add to or potentiate the action of other antihypertensive drugs. (Klortalidon etiketi, İlaç etkileşimleri)

  • NiasinOrta

    Antihypertensive Therapy Niacin may potentiate the effects of ganglionic blocking agents and vasoactive drugs resulting in postural hypotension. (Niasin etiketi, İlaç etkileşimleri)

  • Nifedipindihidropiridin kalsiyum kanal blokeriOrta

    Effect of chlorthalidone on other drugs Chlorthalidone may add to or potentiate the action of other antihypertensive drugs. (Klortalidon etiketi, İlaç etkileşimleri)

  • Nikardipindihidropiridin kalsiyum kanal blokeriOrta

    Effect of chlorthalidone on other drugs Chlorthalidone may add to or potentiate the action of other antihypertensive drugs. (Klortalidon etiketi, İlaç etkileşimleri)

  • Nimodipindihidropiridin kalsiyum kanal blokeriOrta

    Blood Pressure Lowering Drugs Nimodipine may increase the blood pressure lowering effect of concomitantly administered anti-hypertensives such as diuretics, beta-blockers, ACE inhibitors, angiotensin receptor blockers, other calcium channel blockers, α-adrenergic blockers, PDE5 inhibitors, and α-methyldopa. (Nimodipin etiketi, İlaç etkileşimleri)

  • Nisoldipindihidropiridin kalsiyum kanal blokeriOrta

    Effect of chlorthalidone on other drugs Chlorthalidone may add to or potentiate the action of other antihypertensive drugs. (Klortalidon etiketi, İlaç etkileşimleri)

  • NitrogliserinnitratOrta

    Antihypertensives: Possible additive hypotensive effects. (Nitrogliserin etiketi, İlaç etkileşimleri)

  • NitroprussidvazodilatörOrta

    Effect of chlorthalidone on other drugs Chlorthalidone may add to or potentiate the action of other antihypertensive drugs. (Klortalidon etiketi, İlaç etkileşimleri)

  • OksaprozinNSAİİOrta

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (Oksaprozin etiketi, Uyarılar ve önlemler)

  • OksikodonopioidOrta

    Examples: cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Oksikodon etiketi, İlaç etkileşimleri)

  • Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Oksikodon ve parasetamol etiketi, İlaç etkileşimleri)

  • OksimorfonopioidOrta

    Examples: butorphanol, nalbuphine, pentazocine, buprenorphine Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Oksimorfon etiketi, İlaç etkileşimleri)

  • OlanzapinantipsikotikOrta

    …of myocardial infarction or ischemia, heart failure, or conduction abnormalities), cerebrovascular disease, and conditions which would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications) where the occurrence of syncope, or hypotension and/or bradycardia might put the patient at increased medical risk. (Olanzapin etiketi, Uyarılar ve önlemler)

  • Olanzapin ve fluoksetinantipsikotikOrta

    …and fluoxetine capsules should be used with particular caution in patients with known cardiovascular disease (history of myocardial infarction or ischemia, heart failure, or conduction abnormalities), cerebrovascular disease, or conditions that would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications). (Olanzapin ve fluoksetin etiketi, Uyarılar ve önlemler)

  • OliseridinopioidOrta

    Examples: cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Oliseridin etiketi, İlaç etkileşimleri)

  • Olmesartananjiyotensin II reseptör blokeri (ARB)Orta

    Effect of chlorthalidone on other drugs Chlorthalidone may add to or potentiate the action of other antihypertensive drugs. (Klortalidon etiketi, İlaç etkileşimleri)

  • Olmesartan ve hidroklorotiyazidanjiyotensin II reseptör blokeri (ARB)Orta

    Effect of chlorthalidone on other drugs Chlorthalidone may add to or potentiate the action of other antihypertensive drugs. (Klortalidon etiketi, İlaç etkileşimleri)

  • Olmesartan, amlodipin ve hidroklorotiyazidanjiyotensin II reseptör blokeri (ARB)Orta

    Effect of chlorthalidone on other drugs Chlorthalidone may add to or potentiate the action of other antihypertensive drugs. (Klortalidon etiketi, İlaç etkileşimleri)

  • Omeprazolproton pompası inhibitörüOrta

    For patients expected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), health care professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically [see Adverse Reactions ( 6.2 )] . (Omeprazol etiketi, Uyarılar ve önlemler)

  • Omeprazol ve sodyum bikarbonatproton pompası inhibitörüOrta

    For patients expected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), health care professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically [see Adverse Reactions ( 6.2 )] . (Omeprazol ve sodyum bikarbonat etiketi, Uyarılar ve önlemler)

  • PaliperidonantipsikotikOrta

    Use ERZOFRI with caution in patients with known cardiovascular disease (e.g., heart failure, history of myocardial infarction or ischemia, conduction abnormalities), cerebrovascular disease, or conditions that predispose the patient to hypotension (e.g., dehydration, hypovolemia, and treatment with antihypertensive medications). (Paliperidon etiketi, Uyarılar ve önlemler)

  • Pantoprazolproton pompası inhibitörüOrta

    For patients expected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), health care professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically [see Adverse Reactions (6.2) ]. (Pantoprazol etiketi, Uyarılar ve önlemler)

  • • Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (Parasetamol ve ibuprofen etiketi, Uyarılar ve önlemler)

  • Diuretics Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Parasetamol ve kodein etiketi, İlaç etkileşimleri)

  • ParikalsitolD vitamini analoğuOrta

    The risk may be increased when Paricalcitol Injection is used concomitantly with high dose calcium preparations, thiazide diuretics, or vitamin D compounds. (Parikalsitol etiketi, Uyarılar ve önlemler)

  • ParoksetinSSRIOrta

    Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SNRIs and SSRIs. [see Use in Specific Populations ( 8.5 )]. (Paroksetin etiketi, Uyarılar ve önlemler)

  • Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (Pazopanib etiketi, Uyarılar ve önlemler)

  • Diuretics Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Pentazosin ve nalokson etiketi, İlaç etkileşimleri)

  • PentoksifilinmetilksantinOrta

    Small decreases in blood pressure have been observed in some patients treated with pentoxifylline extended-release tablets; periodic systemic blood pressure monitoring is recommended for patients receiving concomitant antihypertensive therapy. (Pentoksifilin etiketi, İlaç etkileşimleri)

  • PerindoprilACE inhibitörüOrta

    Effect of chlorthalidone on other drugs Chlorthalidone may add to or potentiate the action of other antihypertensive drugs. (Klortalidon etiketi, İlaç etkileşimleri)

  • PetidinopioidOrta

    Examples: Cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Petidin etiketi, İlaç etkileşimleri)

  • Pindololbeta blokerOrta

    Effect of chlorthalidone on other drugs Chlorthalidone may add to or potentiate the action of other antihypertensive drugs. (Klortalidon etiketi, İlaç etkileşimleri)

  • Pioglitazon ve glimepiridtiyazolidindionOrta

    …glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol,… (Pioglitazon ve glimepirid etiketi, İlaç etkileşimleri)

  • PiroksikamNSAİİOrta

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. (Piroksikam etiketi, Uyarılar ve önlemler)

  • Concurrent use with potassium-containing medications, potassium-sparing diuretics and angiotensin-converting enzyme inhibitors (ACE inhibitors) may result in hyperkalemia and cardiac arrhythmias or cardiac arrest. (Potasyum iyodür etiketi, İlaç etkileşimleri)

  • Prazosinalfa blokerOrta

    Effect of chlorthalidone on other drugs Chlorthalidone may add to or potentiate the action of other antihypertensive drugs. (Klortalidon etiketi, İlaç etkileşimleri)

  • ProklorperazinantipsikotikOrta

    Thiazide diuretics may accentuate the orthostatic hypotension that may occur with phenothiazines. (Proklorperazin etiketi, Önlemler)

  • Diuretics : Codeine may reduce the efficacy of diuretics. (Prometazin ve kodein etiketi, İlaç etkileşimleri)

  • Propranololbeta blokerOrta

    Effect of chlorthalidone on other drugs Chlorthalidone may add to or potentiate the action of other antihypertensive drugs. (Klortalidon etiketi, İlaç etkileşimleri)

  • Rabeprazolproton pompası inhibitörüOrta

    For patients expected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), health care professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically [see Adverse Reactions (6.2) ]. (Rabeprazol etiketi, Uyarılar ve önlemler)

  • RamiprilACE inhibitörüOrta

    Effect of chlorthalidone on other drugs Chlorthalidone may add to or potentiate the action of other antihypertensive drugs. (Klortalidon etiketi, İlaç etkileşimleri)

  • RiosiguatvazodilatörOrta

    Consider the potential for symptomatic hypotension or ischemia in patients with hypovolemia, severe left ventricular outflow obstruction, resting hypotension, autonomic dysfunction, or concomitant treatment with antihypertensives or strong CYP and P-gp/BCRP inhibitors [see Drug Interactions (7.2) and Clinical Pharmacology (12.3) ] . (Riosiguat etiketi, Uyarılar ve önlemler)

  • RisperidonantipsikotikOrta

    Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (Risperidon etiketi, Uyarılar ve önlemler)

  • Sakubitril ve valsartananjiyotensin II reseptör blokeri (ARB)Orta

    Effect of chlorthalidone on other drugs Chlorthalidone may add to or potentiate the action of other antihypertensive drugs. (Klortalidon etiketi, İlaç etkileşimleri)

  • Salbutamolbeta adrenerjik agonistOrta

    Diuretics: Use with caution. (Salbutamol etiketi, İlaç etkileşimleri)

  • Salmeterolbeta adrenerjik agonistOrta

    • Diuretics: Use with caution. (Salmeterol etiketi, İlaç etkileşimleri)

  • SalsalatNSAİİOrta

    Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors, and the elderly. (Salsalat etiketi, Uyarılar)

  • SefepimsefalosporinOrta

    Diuretics: Nephrotoxicity has been reported with concomitant administration of cephalosporins with potent diuretics such as furosemide. (Sefepim etiketi, İlaç etkileşimleri)

  • SeftazidimsefalosporinOrta

    Drug Interactions Nephrotoxicity has been reported following concomitant administration of cephalosporins with aminoglycoside antibacterial drugs or potent diuretics such as furosemide. (Seftazidim etiketi, İlaç etkileşimleri)

  • SelekoksibNSAİİOrta

    Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia , heart failure, liver dysfunction, those taking diuretics, ACE inhibitors or the ARBs, and the elderly. (Selekoksib etiketi, Uyarılar ve önlemler)

  • SertralinSSRIOrta

    Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SSRIs [see Use in Specific Populations ( 8.5 )] . (Sertralin etiketi, Uyarılar ve önlemler)

  • Siklobenzaprinkas gevşeticiOrta

    …concomitant use of TONMYA with: MAO inhibitors may be life-threatening [see Contraindications (4) ] , Alcohol, barbiturates, and other CNS depressants may increase the risk of adverse reactions associated with these drugs, Tramadol may increase the seizure risk, Guanethidine or other similar acting drugs may block the antihypertensive action of these drugs. (Siklobenzaprin etiketi, İlaç etkileşimleri)

  • SiklofosfamidimmünosüpresanOrta

    …inhibitors: ACE inhibitors can cause leukopenia. ● Natalizumab ● Paclitaxel: Increased hematotoxicity has been reported when cyclophosphamide was administered after paclitaxel infusion. ● Thiazide diuretics ● Zidovudine Increased cardiotoxicity ● Anthracyclines ● Cytarabine ● Pentostatin ● Radiation therapy of the cardiac region ● Trastuzumab Increased pulmonary toxicity… (Siklofosfamid etiketi, İlaç etkileşimleri)

  • SildenafilPDE5 inhibitörüOrta

    Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. (Sildenafil etiketi, Uyarılar ve önlemler)

  • Silodosinalfa blokerOrta

    However, patients in the Phase 3 clinical studies taking concomitant antihypertensive medications with silodosin capsules did not experience a significant increase in the incidence of syncope, dizziness, or orthostasis. (Silodosin etiketi, Uyarılar ve önlemler)

  • SitalopramSSRIOrta

    Elderly patients, patients taking diuretics, and those who are volume depleted may be at greater risk for developing hyponatremia with SSRIs [see Use in Specific Populations ( 8.5 )] . (Sitalopram etiketi, Uyarılar ve önlemler)

  • Increase the dose of diuretics as needed [see Adverse Reactions (6) ] . (Sodyum zirkonyum siklosilikat etiketi, Uyarılar ve önlemler)

  • Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (Sorafenib etiketi, Uyarılar ve önlemler)

  • Sotalolbeta blokerOrta

    Special attention should be given to electrolyte and acid-base balance in patients experiencing severe or prolonged diarrhea or patients receiving concomitant diuretic drugs. (Sotalol etiketi, Uyarılar ve önlemler)

  • Spironolaktonaldosteron antagonistiOrta

    Effect of chlorthalidone on other drugs Chlorthalidone may add to or potentiate the action of other antihypertensive drugs. (Klortalidon etiketi, İlaç etkileşimleri)

  • Spironolakton ve hidroklorotiyazidaldosteron antagonistiOrta

    Effect of chlorthalidone on other drugs Chlorthalidone may add to or potentiate the action of other antihypertensive drugs. (Klortalidon etiketi, İlaç etkileşimleri)

  • SulindakNSAİİOrta

    Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors, patients who are volume-depleted, and the elderly. (Sulindak etiketi, Uyarılar)

  • Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors or ARBs, and the elderly. (Sumatriptan ve naproksen etiketi, Uyarılar ve önlemler)

  • Initiate and/or adjust antihypertensive therapy as appropriate. (Sunitinib etiketi, Uyarılar ve önlemler)

  • Süksinilkolinnöromüsküler blokerOrta

    Prolonged Neuromuscular Block in Patients with Hypokalemia or Hypocalcemia Neuromuscular blockade may be prolonged in patients with hypokalemia (e.g., after severe vomiting, diarrhea, digitalisation and diuretic therapy) or hypocalcemia (e.g., after massive transfusions). (Süksinilkolin etiketi, Uyarılar ve önlemler)

  • TakrolimusimmünosüpresanOrta

    • Hypertension: May require antihypertensive therapy; monitor relevant drug interactions. (Takrolimus etiketi, Uyarılar ve önlemler)

  • TapentadolopioidOrta

    …use of skeletal muscle relaxants and opioids, consider prescribing naloxone for the emergency treatment of opioid overdose [see Dosage and Administration (2.2) , Warnings and Precautions (5.2 , 5.3) ] Examples: cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Tapentadol etiketi, İlaç etkileşimleri)

  • Telmisartananjiyotensin II reseptör blokeri (ARB)Orta

    Effect of chlorthalidone on other drugs Chlorthalidone may add to or potentiate the action of other antihypertensive drugs. (Klortalidon etiketi, İlaç etkileşimleri)

  • Telmisartan ve amlodipinanjiyotensin II reseptör blokeri (ARB)Orta

    Effect of chlorthalidone on other drugs Chlorthalidone may add to or potentiate the action of other antihypertensive drugs. (Klortalidon etiketi, İlaç etkileşimleri)

  • Telmisartan ve hidroklorotiyazidanjiyotensin II reseptör blokeri (ARB)Orta

    Effect of chlorthalidone on other drugs Chlorthalidone may add to or potentiate the action of other antihypertensive drugs. (Klortalidon etiketi, İlaç etkileşimleri)

  • Terazosinalfa blokerOrta

    Effect of chlorthalidone on other drugs Chlorthalidone may add to or potentiate the action of other antihypertensive drugs. (Klortalidon etiketi, İlaç etkileşimleri)

  • Terbutalinbeta adrenerjik agonistOrta

    Diuretics The ECG changes and/or hypokalemia that may result from the administration of non-potassium sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. (Terbutalin etiketi, Önlemler)

  • TestosteronandrojenOrta

    In patients with hypertension on antihypertensive therapy, TLANDO increased the mean systolic/diastolic BP by 4.8/1.6 mm Hg from baseline. [see Adverse Reactions ( 6.1 )] . (Testosteron etiketi, Uyarılar ve önlemler)

  • Tizanidinkas gevşeticiOrta

    Effect of chlorthalidone on other drugs Chlorthalidone may add to or potentiate the action of other antihypertensive drugs. (Klortalidon etiketi, İlaç etkileşimleri)

  • TobramisinaminoglikozidOrta

    Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (Tobramisin etiketi, İlaç etkileşimleri)

  • TolmetinNSAİİOrta

    Use of tolmetin may blunt the CV effects of several therapeutic agents used to treat these medical conditions [e.g., diuretics, ACE inhibitors, or angiotensin receptor blockers (ARBs)] (see PRECAUTIONS: Drug Interactions ). (Tolmetin etiketi, Uyarılar)

  • Co-administration of diuretics also increases the risk of too rapid correction of serum sodium and such patients should undergo close monitoring of serum sodium. (Tolvaptan etiketi, Uyarılar ve önlemler)

  • Torasemidkıvrım (loop) diüretiğiOrta

    Effect of chlorthalidone on other drugs Chlorthalidone may add to or potentiate the action of other antihypertensive drugs. (Klortalidon etiketi, İlaç etkileşimleri)

  • Toremifenselektif östrojen reseptör modülatörüOrta

    Drugs that decrease renal calcium excretion, e.g., thiazide diuretics, may increase the risk of hypercalcemia in patients receiving FARESTON. (Toremifen etiketi, İlaç etkileşimleri)

  • TramadolopioidOrta

    Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Tramadol etiketi, İlaç etkileşimleri)

  • Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Tramadol ve parasetamol etiketi, İlaç etkileşimleri)

  • TrandolaprilACE inhibitörüOrta

    Effect of chlorthalidone on other drugs Chlorthalidone may add to or potentiate the action of other antihypertensive drugs. (Klortalidon etiketi, İlaç etkileşimleri)

  • TrazodonantidepresanOrta

    Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (Trazodon etiketi, Uyarılar ve önlemler)

  • Triamterenpotasyum tutucu diüretikOrta

    Effect of chlorthalidone on other drugs Chlorthalidone may add to or potentiate the action of other antihypertensive drugs. (Klortalidon etiketi, İlaç etkileşimleri)

  • Triamteren ve hidroklorotiyazidpotasyum tutucu diüretikOrta

    Effect of chlorthalidone on other drugs Chlorthalidone may add to or potentiate the action of other antihypertensive drugs. (Klortalidon etiketi, İlaç etkileşimleri)

  • TrifluoperazinantipsikotikOrta

    Thiazide diuretics may accentuate the orthostatic hypotension that may occur with phenothiazines. (Trifluoperazin etiketi, Önlemler)

  • Umeklidinyum ve vilanterolantikolinerjikOrta

    • Diuretics: Use with caution. (Umeklidinyum ve vilanterol etiketi, İlaç etkileşimleri)

  • Valsartananjiyotensin II reseptör blokeri (ARB)Orta

    Effect of chlorthalidone on other drugs Chlorthalidone may add to or potentiate the action of other antihypertensive drugs. (Klortalidon etiketi, İlaç etkileşimleri)

  • Valsartan ve hidroklorotiyazidanjiyotensin II reseptör blokeri (ARB)Orta

    Effect of chlorthalidone on other drugs Chlorthalidone may add to or potentiate the action of other antihypertensive drugs. (Klortalidon etiketi, İlaç etkileşimleri)

  • VardenafilPDE5 inhibitörüOrta

    Vardenafil hydrochloride tablets can potentiate the hypotensive effects of nitrates, alpha- blockers, and antihypertensives. (Vardenafil etiketi, İlaç etkileşimleri)

  • VenlafaksinSNRIOrta

    Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (Venlafaksin etiketi, Uyarılar ve önlemler)

  • Verapamilkalsiyum kanal blokeriOrta

    Effect of chlorthalidone on other drugs Chlorthalidone may add to or potentiate the action of other antihypertensive drugs. (Klortalidon etiketi, İlaç etkileşimleri)

  • VilazodonSSRIOrta

    Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SSRIs and SNRIs [see Use in Specific Populations ( 8.5 )] . (Vilazodon etiketi, Uyarılar ve önlemler)

  • VortioksetinantidepresanOrta

    Also, patients taking diuretics or who are otherwise volume-depleted can be at greater risk. (Vortioksetin etiketi, Uyarılar ve önlemler)

  • ZiprasidonantipsikotikOrta

    Hypokalemia may result from diuretic therapy, diarrhea, and other causes. (Ziprasidon etiketi, Uyarılar ve önlemler)

  • Zoledronik asitbifosfonatOrta

    Elderly patients and those receiving diuretic therapy are at increased risk of acute renal failure. (Zoledronik asit etiketi, Uyarılar ve önlemler)

Minör değinmeler (44)

  • AkarbozantidiyabetikMinör

    These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel-blocking drugs, and isoniazid. (Akarboz etiketi, İlaç etkileşimleri)

  • Patients required intervention with a diuretic, fluid management, or, in some cases, hospitalization for decompensating heart failure. (Ambrisentan etiketi, Uyarılar ve önlemler)

  • BosentanCYP3A4 indükleyicisiMinör

    Patients required intervention with a diuretic, fluid management, or hospitalization for decompensating heart failure. (Bosentan etiketi, Uyarılar ve önlemler)

  • ButorfanolopioidMinör

    In such cases, butorphanol should be discontinued and the hypertension treated with antihypertensive drugs. (Butorfanol etiketi, Uyarılar)

  • ÇinkoVitamin ve mineralMinör

    Tiyazid diüretikler uzun süreli kullanımda idrarla çinko kaybını artırır. (NIH Office of Dietary Supplements, Zinc)

  • DasatinibMinör

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib etiketi, Uyarılar ve önlemler)

  • DekstroamfetaminMSS uyarıcısıMinör

    Examples of alkalinizing agents include gastrointestinal alkalinizing agents (e.g., sodium bicarbonate) and urinary alkalinizing agents (e.g. acetazolamide, some thiazides). (Dekstroamfetamin etiketi, İlaç etkileşimleri)

  • Desogestrel ve etinilestradioloral kontraseptifMinör

    If other contraceptive methods are not suitable, hormonal contraceptive therapy may continue combined with antihypertensive therapy. (Desogestrel ve etinilestradiol etiketi, Uyarılar)

  • Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (Dosetaksel etiketi, Uyarılar ve önlemler)

  • DronedaronantiaritmikMinör

    Hypokalemia and Hypomagnesemia with Potassium-Depleting Diuretics Hypokalemia or hypomagnesemia may occur with concomitant administration of potassium-depleting diuretics. (Dronedaron etiketi, Uyarılar ve önlemler)

  • EfedrinsempatomimetikMinör

    Examples: α-adrenergic antagonists, β-adrenergic receptor antagonists, reserpine, quinidine, mephentermine Other Drug Interactions G u anethidine C linical Impact: Ephedrine may inhibit the neuron blockage produced by guanethidine, resulting in loss of antihypertensive effectiveness. (Efedrin etiketi, İlaç etkileşimleri)

  • In addition to discontinuation of the drug, diuretic therapy may be required. (Esterifiye östrojenler ve metiltestosteron etiketi, Uyarılar)

  • Finasterid5-alfa redüktaz inhibitörüMinör

    …clinical studies with acetaminophen, acetylsalicylic acid, α-blockers, angiotensin-converting enzyme (ACE) inhibitors, analgesics, anti-convulsants, beta-adrenergic blocking agents, diuretics, calcium channel blockers, cardiac nitrates, HMG-CoA reductase inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs), benzodiazepines, H 2 antagonists and quinolone anti-infectives… (Finasterid etiketi, İlaç etkileşimleri)

  • FlekainidantiaritmikMinör

    Flecainide acetate has been used in a large number of patients receiving diuretics without apparent interaction. (Flekainid etiketi, İlaç etkileşimleri)

  • GlibenklamidsülfonilüreMinör

    These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (Glibenklamid etiketi, İlaç etkileşimleri)

  • Glibenklamid ve metforminsülfonilüreMinör

    Examples: Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. (Glibenklamid ve metformin etiketi, İlaç etkileşimleri)

  • Glipizid ve metforminsülfonilüreMinör

    These drugs include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (Glipizid ve metformin etiketi, Önlemler)

  • ACE Inhibitors FIRAZYR is a bradykinin B2 receptor antagonist and thereby has the potential to have a pharmacodynamic interaction with ACE inhibitors where FIRAZYR may attenuate the antihypertensive effect of ACE inhibitors. (İkatibant etiketi, İlaç etkileşimleri)

  • İmatinibCYP3A4 inhibitörüMinör

    Weigh patients regularly and manage unexpected rapid weight gain by drug interruption and diuretics. (İmatinib etiketi, Uyarılar ve önlemler)

  • KalsiyumVitamin ve mineralMinör

    Tiyazid diüretikler kalsiyum atılımını azaltır; bu nedenle yüksek kalsiyum alımı kandaki kalsiyumu yükseltebilir. (NIH Office of Dietary Supplements, Calcium)

  • Drugs that may cause hypercalcemia: Vitamin D, vitamin A, thiazide diuretics, estrogen, calcipotriene and teriparatide administration may cause hypercalcemia. (Kalsiyum glukonat etiketi, İlaç etkileşimleri)

  • Acthar Gel may accentuate the electrolyte loss associated with diuretic therapy. (Kortikotropin etiketi, İlaç etkileşimleri)

  • Linagliptin ve metforminDPP-4 inhibitörüMinör

    These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (Linagliptin ve metformin etiketi, İlaç etkileşimleri)

  • MagnezyumVitamin ve mineralMinör

    Kıvrım (loop) diüretiklerinin ve tiyazid diüretiklerin uzun süreli kullanımı idrarla magnezyum kaybını artırır. (NIH Office of Dietary Supplements, Magnesium)

  • Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported [see Adverse Reactions (6.2) ] . (Masitentan etiketi, Uyarılar ve önlemler)

  • MeksiletinantiaritmikMinör

    In a large compassionate use program mexiletine has been used concurrently with commonly employed antianginal, antihypertensive, and anticoagulant drugs without observed interactions. (Meksiletin etiketi, İlaç etkileşimleri)

  • MetforminbiguanidMinör

    Examples: Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. (Metformin etiketi, İlaç etkileşimleri)

  • MetilprednizolonkortikosteroidMinör

    Amphotericin B injection and potassium-depleting agents : When corticosteroids are administered concomitantly with potassium-depleting agents (e.g., amphotericin B, diuretics), patients should be observed closely for development of hypokalemia. (Metilprednizolon etiketi, İlaç etkileşimleri)

  • MetiltestosteronandrojenMinör

    In addition to discontinuation of the drug, diuretic therapy may be required. (Metiltestosteron etiketi, Uyarılar)

  • MilrinonPDE3 inhibitörüMinör

    …been observed in limited experience with patients in whom milrinone was used concurrently with the following drugs: digitalis glycosides; lidocaine, quinidine; hydralazine, prazosin; isosorbide dinitrate, nitroglycerin; chlorthalidone, furosemide, hydrochlorothiazide, spironolactone; captopril; heparin, warfarin, diazepam, insulin; and potassium supplements. (Milrinon etiketi, İlaç etkileşimleri)

  • Nortriptilintrisiklik antidepresanMinör

    The antihypertensive action of guanethidine and similar agents may be blocked. (Nortriptilin etiketi, Uyarılar)

  • Penisilin Gpenisilin antibiyotikMinör

    These drugs include: aspirin, phenylbutazone, sulfonamides, indomethacin, thiazide diuretics, furosemide and ethacrynic acid. (Penisilin G etiketi, İlaç etkileşimleri)

  • Pioglitazon ve metformintiyazolidindionMinör

    These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. (Pioglitazon ve metformin etiketi, İlaç etkileşimleri)

  • Piperasilin ve tazobaktampenisilin antibiyotikMinör

    Periodic electrolyte determinations should be performed in patients with low potassium reserves, and the possibility of hypokalemia should be kept in mind with patients who have potentially low potassium reserves and who are receiving cytotoxic therapy or diuretics. (Piperasilin ve tazobaktam etiketi, Uyarılar ve önlemler)

  • PotasyumVitamin ve mineralMinör

    Kıvrım (loop) diüretikleri ve tiyazid diüretikler potasyum kaybını artırır; bazen bunlarla birlikte takviye reçete edilir. (NIH Office of Dietary Supplements, Potassium)

  • PrednizolonkortikosteroidMinör

    Potassium-depleting agents (e.g., diuretics, Amphotericin B): When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (Prednizolon etiketi, İlaç etkileşimleri)

  • PrednizonkortikosteroidMinör

    Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (Prednizon etiketi, İlaç etkileşimleri)

  • Protriptilintrisiklik antidepresanMinör

    Protriptyline may block the antihypertensive effect of guanethidine or similarly acting compounds. (Protriptilin etiketi, Uyarılar)

  • Atypical Antipsychotics (e.g., olanzapine and clozapine), Corticosteroids, Danazol, Diuretics, Estrogens, Glucagon, Isoniazid, Niacin, Oral Contraceptives, Phenothiazines, Progestogens (e.g., in oral contraceptives), Protease inhibitors, Somatropin, Sympathomimetic Agents (e.g., albuterol, epinephrine, terbutaline) and Thyroid Hormones. (Regüler insülin (insan) etiketi, İlaç etkileşimleri)

  • RepaglinidmeglitinidMinör

    Examples: Atypical antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and… (Repaglinid etiketi, İlaç etkileşimleri)

  • Saksagliptin ve metforminDPP-4 inhibitörüMinör

    These medications include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (Saksagliptin ve metformin etiketi, İlaç etkileşimleri)

  • Sitagliptin ve metforminDPP-4 inhibitörüMinör

    Examples: Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. (Sitagliptin ve metformin etiketi, İlaç etkileşimleri)

  • TerbinafinantifungalMinör

    There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, phenytoins, thiazide diuretics, and calcium channel blockers. (Terbinafin etiketi, İlaç etkileşimleri)

  • TriamsinolonkortikosteroidMinör

    Amphotericin B injection and potassium-depleting agents: When corticosteroids are administered concomitantly with potassium-depleting agents ( i.e., amphotericin B, diuretics), patients should be observed closely for development of hypokalemia. (Triamsinolon etiketi, İlaç etkileşimleri)

Anlamlı etkileşim olmadığı bildirilenler (2)

  • PamidronatbifosfonatEtkileşim yok

    Loop Diuretics Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of pamidronate disodium. (Pamidronat etiketi, İlaç etkileşimleri)

  • Ropiniroldopamin agonistiEtkileşim yok

    Commonly Administered Drugs: Population analysis showed that commonly administered drugs (e.g., selegiline, amantadine, tricyclic antidepressants, benzodiazepines, ibuprofen, thiazides, antihistamines, anticholinergics) did not affect the clearance of ropinirole. (Ropinirol etiketi, İlaç etkileşimleri)

Kullandığınız her şeyi Klortalidon ile karşılaştırın. Tüm listenizi ekleyin; her çift tek seferde kontrol edilir.

Sorgulama aracında aç

Tıbbi tavsiye değildir. Şiddet derecesi sizin koşullarınızı değil, etiketin ifadesini yansıtır. “Majör” işareti gözetim altında olağan bir uygulama olabilir, “minör” işareti ise yüksek dozlarda önem kazanabilir. Bir eczacıya danışın.